

CHEERS Checklist for “Cost-effectiveness of palivizumab in term infants who reside in the Canadian Arctic”

1	Title	Page 1
2	Abstract	Page 1
3	Introduction	page 2 line 52 Statement of the broader context for study, Study question relevance for policy or practice decisions. This study would directly impact the use of palivizumab for term Inuit infants who have the highest rates of admission for RSV in the world.
4	Target population	Page 2 & 4, healthy term infants < 6 months of age at the beginning of the RSV season, comparing across different regions of Arctic
5	Setting	Page 3, 45
6	Study perspective	Page 5 line 13, Public payers perspective (territorial governments)
7	comparators	Page 4 line 10-43, Palivizumab prophylaxis vs no prophylaxis of term infants in 3 scenarios. Scenario A continuing prophylaxis to end of RSV season, Scenario B prophylax only up to 5 months of age (6 months protection), Scenario C: Scenario A compared to Scenario B
8	Time horizon	Page 5 line 17, 6 months
9	discounting	Page 6 line 40. no discounting, short time line
10	Choice of health outcomes	Page 4 line 23, RSV admission in the time line Jan 1 to June 30 2009
11a	Measurement of effectiveness	Pg 3, line 50 to page 4 line 17
12	Measurements and valuation of preference based outcomes	Table 1
13a	Estimating resources or costs	Page 5 line 51, summarized Table 2, Actual costs where possible from governments, or contracting agencies. If estimate then minimal estimates were used (no extra costs for afterhours, outpatients, complications etc.)
14	Currency, price conversion	Page 6 line 38, The study used 2011 Canadian dollars which was almost equivalent to US dollars at the time.
15	Choice of model	N/a
16	Assumptions	Page 4, line 17-29 All assumptions were included, including 100 % compliance with palivizumab, vial sharing, equal distribution of births
17	Analytical methods	Page 3 line 47,
18	Study parameters	table 1
19	Incremental costs and outcomes	Table 4-7
20a	Single study base economic evaluation	Based on actual data
21	heterogeneity	Page 9 line 6 The heterogeneity across the Canadian Arctic was described, some hypotheses are discussed
22	discussion	Page 7 line 33
23	Source of funding	Unfunded study
24	Conflict of interest	No COI declared